• Species Reactivity

  Human

• Specificity

  Detects human IFN-alpha / beta R2 C-Terminus in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) IFN-alpha / beta R2a, rhIFN-alpha / beta R alpha, and recombinant mouse IFN-alpha / beta R2 is observed.

• Source

  Polyclonal Sheep IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  E. coli-derived recombinant human IFN-alpha / beta R2 C-Terminus    
  Ser351-Met514    
  Accession # P48551

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 µg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.2 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha/beta R2

IFN-alpha / beta R2 (Interferon alpha/beta receptor 2/IFNAR2; also IFN alpha binding protein) is a 90-102 kDa member of the class II cytokine receptor family of molecules. It is expressed on hematopoietic cells, including T cells, NK cells, B cells and monocytes. It serves as a ligand binding subunit for type I IFN, and generates a functional IFN receptor by complexing with 125 kDa IFNAR1. Multiple type I IFNs signal through this heterodimeric receptor with distinct outcomes. This may be attributable to unique structural conformations created by the Type I IFN:IFNAR1 interaction, or the use of a truncated isoform of IFNAR2. Mature human IFNAR2 is a 489 amino acid (aa) type I transmembrane glycoprotein (aa 27-515). It contains a 217 aa extracellular region (aa 27-243) that contains an Ig-like domain (aa 39-118), a fibronectin type III domain, and a 251 aa cytoplasmic tail. There are two isoform variants. The first is 50-55 kDa in size and contains a 51 aa substitution for aa 281-515. The second is a 40 kDa soluble form that shows a two aa substitution for aa 238-515. IFNAR2 also undergoes proteolysis. Cleavage of the 92 kDa isoform generates a 58 kDa membrane-embedded stub that can be further cleaved into 27-35 kDa fragments that undergo nuclear translocation. Over aa 351-514. human IFNAR2 shares 48% aa identity with mouse IFNAR2.

• Long Name:

  Interferon alpha/beta Receptor 2

• Entrez Gene IDs:

  3455 (Human); 15976 (Mouse)

• Alternate Names:

  beta receptor10; human interferon alpha; human interferon alpha/beta receptor; IFNABR; IFN-alpha binding protein; IFN-alpha/beta R2; IFN-alpha/beta receptor 2; IFN-alpha-REC; IFNAR2; IFN-aR2; IFNARB; IFNbR2; IFN-bR2; IFN-R; IFN-R-2; interferon (alpha, beta and omega) receptor 2; Interferon alpha binding protein; interferon alpha/beta receptor 2; interferon-alpha/beta receptor beta chain; Type I interferon receptor 2